Middle East Pharmaceutical Industries Company
Middle East Pharmaceutical Industries Company (4016.SR) Revenue
Annual & quarterly revenue history · segment & region breakdown
4016.SR · revenue · updated Jun 15, 2026
Core revenue metrics
Trailing 12 monthsMiddle East Pharmaceutical Industries Company trailing twelve-month (TTM) revenue is $0.49B, an increase of 16.87% year-over-year from $0.46B in FY2025.
Revenue trend
2025 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.46B | +$0.07B | +16.87% |
| 2024-12-31 | $0.39B | +$0.06B | +16.42% |
| 2023-12-31 | $0.34B | +$0.04B | +11.82% |
| 2022-12-31 | $0.30B | +$0.02B | +5.38% |
| 2021-12-31 | $0.29B | -$0.01B | -4.79% |
| 2020-12-31 | $0.30B | +$0.07B | +29.97% |
| 2019-12-31 | $0.23B | — | — |
Compare revenue vs peers
Medical - PharmaceuticalsCompare 4016.SR revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Middle East Pharmaceutical Industries Company receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Middle East Pharmaceutical Industries Company reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in SAR.
Data sourced from Middle East Pharmaceutical Industries Company's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
4016.SR revenue · 4 questions4016.SR's trailing twelve-month (TTM) revenue is $0.49B. That is an increase of 16.87% year-over-year from $0.46B in FY2025.
▸ Source: FMP · Middle East Pharmaceutical Industries Company SEC filings · GAAP · Middle East Pharmaceutical Industries Company SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 15, 2026